IMTX

Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Immatics (IMTX - Research Report) today and set a price target of $28.00. The company's shares closed today at $10.26.Livshits covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals, Intellia Therapeutics, and Immatics. According to TipRanks, Livshits has an average return of 25.9% and a 41.91% success rate on recommended stocks. Immatics has an analyst consensus of Moderate Buy, with a price target consensus of $28.00.See the top stocks recommended by analysts >>Based on Immatics' latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $17.
https://www.tipranks.com/news/blurbs/chardan-capital-sticks-to-their-buy-rating-for-immatics-imtx?utm_source=advfn.com&utm_medium=referral